Hospital.Help

Berlin – The recent numerous investments by the pharmaceutical industry in Germany are, according to Chancellor Olaf Scholz (SPD), the result of government action. He spoke today of a “successful supply policy”.

The companies are aware of the draft laws and are making “their investment decisions” on the basis of them, the Chancellor said during a government questioning session in the Bundestag. He referred, among other things, to the government’s pharmaceutical strategy, which is “of great importance” in the companies’ considerations for their investment strategies.

He also cited the Health Data Use Act and digitization in the health care system as examples, which have created the conditions for a better research landscape. The Medical Research Act, which will be finally adopted in the Bundestag tomorrow, also belongs in this series. Among other things, it concerns the confidentiality of reimbursement prices.

Scholz went on to say that they were determined to remove all bureaucratic obstacles that were hindering Germany as a location for pharmaceutical research. “This is underway and is being taken very seriously,” said the Chancellor.

All of this is leading to “billions in investments” by the pharmaceutical industry in Germany. These are also coming from companies in other countries, some of which are also settling in Germany and building large production facilities. In recent months, Eli Lilly and Abbvie, among others, have begun investments in Germany.

Scholz predicted that there would be “many additional jobs, in all categories.” This ranges from simple jobs for skilled and unskilled workers to research facilities with highly qualified, internationally experienced experts.

“It’s this mix that makes it, to put it quite clearly. Not to mention the trades that benefit when such sites are built and constructed,” said the Chancellor.

The recently announced investment by Sanofi is another example of how Germany is further expanding its reputation as the pharmacy of the world, as a “substantial research and production location” for the pharmaceutical industry and as a special medical and research location. © may/aerzteblatt.de